Antonio
Pérez Martínez
Antonio Pérez Martínez-rekin lankidetzan egindako argitalpenak (11)
2023
-
NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells
Frontiers in Immunology, Vol. 14
-
Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study
BMJ open, Vol. 13, Núm. 7, pp. e071371
2022
2021
-
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
Blood Cancer Journal, Vol. 11, Núm. 8
-
Natural killer cells efficiently target multiple myeloma clonogenic tumor cells
Cancer Immunology, Immunotherapy, Vol. 70, Núm. 10, pp. 2911-2924
-
Optimizing the procedure to manufacture clinical‐grade NK cells for adoptive immunotherapy
Cancers, Vol. 13, Núm. 3, pp. 1-24
-
Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL–Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 5, pp. 328-337.e1
2019
-
GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy
Frontiers in Immunology, Vol. 10
2018
-
Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia
Cancer Letters, Vol. 422, pp. 107-117
-
How do we manufacture clinical-grade interleukin-15–stimulated natural killer cell products for cancer treatment?
Transfusion, Vol. 58, Núm. 6, pp. 1340-1347